COVID-19 Third Dose Vaccine Protection Against Hospitalization Wanes After 3 Months

Three COVID-19 Vaccine Doses

A brand new analysis examine printed in The Lancet Respiratory Medicine reveals that safety towards the omicron variant deteriorates over time – even after a 3rd vaccine dose.

Kaiser Permanente finds the Pfizer (*3*)COVID-19 third dose vaccine safety towards hospitalization from omicron wanes after 3 months.

A analysis examine launched on April 22, 2022, in The Lancet Respiratory Medicine reveals {that a} booster dose of the Pfizer COVID-19 vaccine offers sturdy safety, roughly 80% to 90%, within the first few months towards hospital admissions and emergency division visits attributable to the delta and omicron variants of COVID-19. However, this safety towards omicron deteriorates over time – even after a 3rd vaccine dose.

“Pfizer BioNTech COVID-19 booster doses considerably enhance safety towards omicron, though that safety appears to wane after 3 months towards emergency room visits, and even for hospitalization,” stated the examine’s lead writer, Sara Y. Tartof, PhD, an epidemiologist with the Kaiser Permanente Southern California Department of Research & Evaluation and a school member of the Kaiser Permanente Bernard J. Tyson School of Medicine, each in Pasadena. “Trends in waning towards delta-related outcomes had been typically much like omicron, however with greater effectiveness at every time level than these seen for omicron.”

The researchers examined 11,123 hospital admissions and emergency division visits that didn’t lead to hospitalization for acute respiratory an infection for this examine. The researchers checked out Kaiser Permanente affected person data in Southern California from December 1, 2021, to February 6, 2022, when each the delta and omicron variants had been circulating within the inhabitants.

  • After 2 doses of the Pfizer COVID-19 vaccine effectiveness towards omicron was 41% towards hospital admission and 31% towards emergency division visits at 9 months.
  • After 3 doses, effectiveness towards omicron-related hospitalization was 85% at lower than 3 months however fell to 55% at 3 months or longer.
  • Against emergency division visits that didn’t lead to hospitalization, vaccine effectiveness of 3 doses towards omicron was 77% at lower than 3 months however fell to 53% at 3 months or longer.

“Although the Pfizer COVID-19 safety ranges towards omicron after 3 doses are considerably greater than these seen after 2 doses, they’re lower than these noticed for delta or different COVID-19 strains,” Tartof stated. “Additional doses of present, tailored, or novel COVID-19 vaccines could also be wanted to keep up excessive ranges of safety towards subsequent waves of COVID-19 attributable to omicron or future variants with related potential to flee safety.”

Reference: “Durability of BNT162b2 vaccine towards hospital and emergency division admissions as a result of omicron and delta variants in a big well being system within the USA: a test-negative case–management examine” by Sara Y Tartof, PhD; Jeff M Slezak, MS; Laura Puzniak, PhD; Vennis Hong, MPH; Fagen Xie, PhD; Bradley K Ackerson, MD; Srinivas R Valluri, PhD; Luis Jodar, PhD and John M McLaughlin, PhD, 22 April 2022, The Lancet Respiratory Medicine.
DOI: 10.1016/S2213-2600(22)00101-1



Source link